Abstract:This comprehensive review delves into the pivotal role of mitochondria in doxorubicin-induced cardiotoxicity, a significant complication limiting the clinical use of this potent anthracycline chemotherapeutic agent. Doxorubicin, while effective against various malignancies, is associated with dose-dependent cardiotoxicity, potentially leading to irreversible cardiac damage. The review meticulously dissects the molecular mechanisms underpinning this cardiotoxicity, particularly focusing on mitochondrial dysfunction, a central player in this adverse effect. Central to the discussion is the concept of mitochondrial quality control, including mitochondrial dynamics (fusion/fission balance) and mitophagy. The review presents evidence linking aberrations in these processes to cardiotoxicity in doxorubicin-treated patients. It elucidates how doxorubicin disrupts mitochondrial dynamics, leading to an imbalance between mitochondrial fission and fusion, and impairs mitophagy, culminating in the accumulation of dysfunctional mitochondria and subsequent cardiac cell damage. Furthermore, the review explores emerging therapeutic strategies targeting mitochondrial dysfunction. It highlights the potential of modulating mitochondrial dynamics and enhancing mitophagy to mitigate doxorubicin-induced cardiac damage. These strategies include pharmacological interventions with mitochondrial fission inhibitors, fusion promoters, and agents that modulate mitophagy. The review underscores the promising results from preclinical studies while advocating for more extensive clinical trials to validate these approaches in human patients. In conclusion, this review offers valuable insights into the intricate relationship between mitochondrial dysfunction and doxorubicin-mediated cardiotoxicity. It underscores the need for continued research into targeted mitochondrial therapies as a means to improve the cardiac safety profile of doxorubicin, thereby enhancing the overall treatment outcomes for cancer patients.

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

[Cardiotoxicity of drugs used in oncology]

Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury

Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

Anthracycline Chemotherapy and Cardiotoxicity

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect

The Cardiotoxicology of Anthracycline Chemotherapeutics

Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches

Doxorubicin induced heart failure: Phenotype and molecular mechanisms

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Cardiotoxicity of doxorubicin – causes, prevention, prospects

Role of mitochondria in doxorubicin-mediated cardiotoxicity: From molecular mechanisms to therapeutic strategies

A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer